Adjunctive use of controlled-release pregabalin in adults with treatment-resistant partial seizures: A double-blind, randomized, placebo-controlled trial

Epilepsia

Volumn 55, Issue 8, 2014, Pages 1220-1228

  French, Jacqueline ^a   Brandt, Christian ^b   Friedman, Daniel ^a   Biton, Victor ^c   Knapp, Lloyd ^d   Pitman, Verne ^d   Chew, Marci ^d   Dubrava, Sarah ^d   Posner, Holly B ^d  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b EPILEPSY CENTER BETHEL   (Germany)

^c Arkansas Epilepsy Program   (United States)

^d PFIZER INC   (United States)

Author keywords

Clinical; Controlled release; Epilepsy; Extended release; Lyrica; Pregabalin

Indexed keywords

CLINICAL; CONTROLLED-RELEASE; EPILEPSY; EXTENDED-RELEASE; LYRICA; PREGABALIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; FOLLOW-UP STUDIES; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84905509126     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12690     Document Type: Article

References (19)

1. Hauser WA, Annegers JF, Rocca WA,. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc 1996; 71: 576-586.
2. World Health Organization. Epilepsy, fact sheet N999, October 2012. World Health Organization; 2012. Available at: http://www.who.int/mediacentre/ factsheets/fs999/en/. Accessed December 23, 2013.
3. Loscher W, Schmidt D,. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011; 52: 657-678.
4. Schmidt D, Sillanpaa M,. Evidence-based review on the natural history of the epilepsies. Curr Opin Neurol 2012; 25: 159-163.
5. Bautista RE, Rundle-Gonzalez V,. Effects of antiepileptic drug characteristics on medication adherence. Epilepsy Behav 2012; 23: 437-441.
6. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 2012; 18: 527-539.
7. Manjunath R, Davis KL, Candrilli SD, et al. Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy Behav 2009; 14: 372-378.
8. Parienti JJ, Bangsberg DR, Verdon R, et al. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis 2009; 48: 484-488.
9. Bialer M,. Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clinical implications. Clin Pharmacokinet 1992; 22: 11-21.
10. ® US prescribing information. Pfizer Inc; 2004. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=561. Accessed August 19, 2013.
11. ® EU product information. Pfizer Inc.; 2009. Available at: http://www.emea.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000546/WC500046602.pdf. Accessed August 19, 2013.
12. Schulze-Bonhage A,. Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy. Expert Opin Drug Metab Toxicol 2013; 9: 105-115.
13. Chew M, Plotka A, Alvey C, et al. Effect of food and dose on pregabalin controlled release pharmacokinetics in healthy volunteers. J Pain 2013; 14: S66 [Abstract].
14. Arroyo S, Anhut H, Kugler AR, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004; 45: 20-27.
15. French JA, Kugler AR, Robbins JL, et al. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003; 60: 1631-1637.
16. French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012; 79: 589-596.
17. Rheims S, Perucca E, Cucherat M, et al. Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia 2011; 52: 219-233.
18. Beydoun A, Uthman BM, Kugler AR, et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005; 64: 475-480.
19. Buvanendran A, Kroin JS, Kari M, et al. Can a single dose of 300 mg of pregabalin reach acute antihyperalgesic levels in the central nervous system? Reg Anesth Pain Med 2010; 35: 535-538.